Home
Conditions
Lymphoproliferative Disorders

Clinical trial condition

Lymphoproliferative Disorders

Explore clinical trials studying Lymphoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,146 public trials 2,034 recruiting studies

Refine in advanced search Browse all conditions

Lymphoproliferative Disorders trial results

Recruiting

Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma

NCT05922501

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +18 more
Locations: Massachusetts General Hospital Boston, Massachusetts, United States

Dana-Farber Cancer Institute Boston, Massachusetts, United States

View Trial Details

Recruiting

Geriatric Evaluation and Management With Survivorship Health Education for Older Survivors of Cancer, GEM-S Trial

NCT05006482

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +6 more
Locations: Lewis and Faye Manderson Cancer Center Tuscaloosa, Alabama, United States

Kaiser Permanente-Fremont Fremont, California, United States

Kaiser Permanente-San Francisco San Francisco, California, United States

Helen F Graham Cancer Center Newark, Delaware, United States

View all 45 locations

View Trial Details

Recruiting

JY232(JY232) Injection in Relapsed/Refractory Multiple Myeloma

NCT07336823

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: Foshan First People's Hospital Foshan, Guangdong, China

View Trial Details

Recruiting

Study Evaluating Safety Pharmacokinetics and Pharmacodynamics of AUR112 in Patients With Relapsed Advanced Lymphoma

NCT06755450

Conditions: Hemic and Lymphatic Diseases, Hodgkin Disease, Immune System Diseases, +8 more
Locations: Sir Sayajirao General Hospital (SSG) Vadodara, Gujarat, India

National Cancer Institute , All India Institute of Medical Sciences Jhajjar, Haryana, India

Health Care Global Enterprises Bangalore, Karnataka, India

Srinivasam Cancer Care Multi Speciality Hospitals India Pvt Ltd. , Bangalore 560072. Bangalore, Karnataka, India

View all 19 locations

View Trial Details

Recruiting

Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RIC

NCT04528355

Conditions: Adrenal Gland Diseases, Adrenal Insufficiency, Adrenoleukodystrophy, +119 more
Locations: UPMC Children's Hospital of Pittsburgh Pittsburgh, Pennsylvania, United States

View Trial Details

Recruiting

Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides

NCT05357794

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations: MD Anderson Cancer Center Houston, Texas, United States

View Trial Details

Recruiting

Study of Naive HBI0101 CAR-T Therapy in Relapsed/Refractory Multiple Myeloma

NCT07333430

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations: Hadassah MO, Jerusalem, 9574869 Jerusalem, Israel

View Trial Details

Recruiting

A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma

NCT03829254

Conditions: Advanced Cancer, Hemic and Lymphatic Diseases, Immune System Diseases, +17 more
Locations: Cambridge University Hospitals NHS Foundation Trust (Addenbrookes Hospital) Cambridge, United Kingdom

Edinburgh Cancer Centre, Western General Hospital Edinburgh, United Kingdom

The Beatson West of Scotland Cancer Centre Glasgow, United Kingdom

University College London Hospital London, United Kingdom

View Trial Details

Recruiting

A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

NCT06776952

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations: Beijing Friendship Hospital,Capital Medical University Beijing, Beijing Municipality, China

View Trial Details

Recruiting

Risk Indicators of Sarcoidosis Evolution-Unified Protocol

NCT05567133

Conditions: Hemic and Lymphatic Diseases, Hypersensitivity, Hypersensitivity, Delayed, +8 more
Locations: University of Maryland Baltimore, Maryland, United States

UT Southwestern Dallas, Texas, United States

View Trial Details

Lymphoproliferative Disorders

Lymphoproliferative Disorders trial results

Related conditions